Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Exendin-4 enhances the migration of adipose-derived stem cells to neonatal rat ventricular cardiomyocyte-derived conditioned medium via the phosphoinositide 3-kinase/Akt-stromal cell-derived factor-1α/CXC chemokine recep

Zhou H., Yang J., Xin T., Zhang T., Hu S., Zhou S.

Animal Study on Cardiovascular Disease, published in Mol Med Rep (2015) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Med Rep (2015)
Country
Greece
Reported sample size
—
Source database
PubMed
PMID
25625935
PMCID
PMC4394957
DOI
10.3892/mmr.2015.3243
Citations
41

Abstract (original English)

Adipose‑derived stem cells (ADSCs) are considered a suitable source of cells for the repair of tissue following acute myocardial infarction (AMI); however, the transplantation efficiency of ADSCs remains low. Therefore, identification of an efficient method to enhance the migration of engrafted cells to the target site is required. The present study used exendin‑4 (Ex‑4), a glucagon‑like peptide‑1 receptor agonist, to optimize the migratory capacity of ADSCs. The aim was to determine the effect and mechanisms of Ex‑4 on the migration of ADSCs to neonatal rat ventricular cardiomyocyte‑derived conditioned medium (NRVC‑CM). The ADSCs and cardiomyocytes were cultured in vitro. Following incubation of the ADSCs with Ex‑4, cell proliferation was measured using an MTT assay and the expression levels of CXC chemokine receptor 4 (CXCR4) were investigated by reverse transctiption quantitative polymerase chain reaction (RT‑qPCR), western blot analysis and flow cytometry. In addition, the expression levels of stromal cell‑derived factor‑1α (SDF‑1α) were evaluated in the NRVC‑CM treated with Ex‑4 by ELISA, RT‑qPCR and western blot analysis. The migration of the ADSCs to the NRVC‑CM was examined using a Transwell assay. Changes in the protein expression levels of phosphorylated (p‑)Akt were examined in the two types of cell by western blot analysis. The results suggested that Ex‑4 promoted t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsCell MovementCells, CulturedChemokine CXCL12ExenatideMaleMyocytes, CardiacPeptidesPhosphatidylinositol 3-Kinases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research